Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

5-Thioxoimidazolidine-2-one derivatives: Synthesis, anti-inflammatory activity, analgesic activity, COX inhibition assay and molecular modelling study.

El-Sharief MAMS, Abbas SY, El-Sharief AMS, Sabry NM, Moussa Z, El-Messery SM, Elsheakh AR, Hassan GS, El Sayed MT.

Bioorg Chem. 2019 Jun;87:679-687. doi: 10.1016/j.bioorg.2019.03.075. Epub 2019 Apr 1.

PMID:
30953887
2.

Design, synthesis, molecular docking and biological activity evaluation of some novel indole derivatives as potent anticancer active agents and apoptosis inducers.

El-Sharief AMS, Ammar YA, Belal A, El-Sharief MAMS, Mohamed YA, Mehany ABM, Elhag Ali GAM, Ragab A.

Bioorg Chem. 2019 Apr;85:399-412. doi: 10.1016/j.bioorg.2019.01.016. Epub 2019 Jan 8.

PMID:
30665034
3.

Failure patterns of head and neck squamous cell carcinoma treated with radical radiotherapy by intensity modulated radiotherapy technique using focal volume and dosimetric method.

Tandon S, Gairola M, Ahlawat P, Karimi AM, Tiwari S, Muttagi V, Sachdeva N, Sharief MI, Dobriyal K.

Head Neck. 2019 Jun;41(6):1632-1637. doi: 10.1002/hed.25586. Epub 2018 Dec 23.

PMID:
30582238
4.

Tetrahydroindolocarbazoles (THICZs) as new class of urokinase (uPA) inhibitors: Synthesis, anticancer evaluation, DNA-damage determination, and molecular modelling study.

El-Sharief MAMS, El-Naggar MH, Ahmed EM, El-Messery SM, Mahmoud AE, Ali MM, Salem LM, Mahrous KF, El Sayed MT.

Bioorg Chem. 2018 Oct;80:545-554. doi: 10.1016/j.bioorg.2018.06.033. Epub 2018 Jun 30.

PMID:
30014922
5.

Design, synthesis, anti-inflammatory activity and molecular docking of potential novel antipyrine and pyrazolone analogs as cyclooxygenase enzyme (COX) inhibitors.

El Sayed MT, El-Sharief MAMS, Zarie ES, Morsy NM, Elsheakh AR, Voronkov A, Berishvili V, Hassan GS.

Bioorg Med Chem Lett. 2018 Mar 1;28(5):952-957. doi: 10.1016/j.bmcl.2018.01.043. Epub 2018 Feb 2.

PMID:
29426771
6.

Design, synthesis, anti-inflammatory antitumor activities, molecular modeling and molecular dynamics simulations of potential naprosyn® analogs as COX-1 and/or COX-2 inhibitors.

El Sayed MT, El-Sharief MAMS, Zarie ES, Morsy NM, Elsheakh AR, Nayel M, Voronkov A, Berishvili V, Sabry NM, Hassan GS, Abdel-Aziz HA.

Bioorg Chem. 2018 Feb;76:188-201. doi: 10.1016/j.bioorg.2017.11.002. Epub 2017 Nov 13.

PMID:
29182950
7.

SodC modulates ras and PKB signaling in Dictyostelium.

Castillo B, Kim SH, Sharief M, Sun T, Kim LW.

Eur J Cell Biol. 2017 Jan;96(1):1-12. doi: 10.1016/j.ejcb.2016.11.001. Epub 2016 Nov 30.

PMID:
27919433
8.
9.

New imidazolidineiminothione derivatives: Synthesis, spectral characterization and evaluation of antitumor, antiviral, antibacterial and antifungal activities.

Moussa Z, El-Sharief MAMS, Abbas SY.

Eur J Med Chem. 2016 Oct 21;122:419-428. doi: 10.1016/j.ejmech.2016.06.051. Epub 2016 Jun 30.

PMID:
27393950
10.

Trimester-Specific Reference Intervals of Thyroid Function Testing in Pregnant Women from Basrah, Iraq Using Electrochemiluminescent Immunoassay.

Almomin AMS, Mansour AA, Sharief M.

Diseases. 2016 Apr 26;4(2). pii: E20. doi: 10.3390/diseases4020020.

11.
12.

Synthesis of thiosemicarbazones derived from N-(4-hippuric acid)thiosemicarbazide and different carbonyl compounds as antimicrobial agents.

El-Sharief MA, Abbas SY, El-Bayouki KA, El-Gammal EW.

Eur J Med Chem. 2013 Sep;67:263-8. doi: 10.1016/j.ejmech.2013.06.031. Epub 2013 Jun 21.

PMID:
23871906
13.

Synthesis and biological evaluation of bis-imidazolidineiminothiones: a comparative study.

El-Sharief MA, Moussa Z, El-Sharief AM.

Arch Pharm (Weinheim). 2013 Jul;346(7):542-55. doi: 10.1002/ardp.201300097.

PMID:
23836516
14.

Thiourea derivatives incorporating a hippuric acid moiety: synthesis and evaluation of antibacterial and antifungal activities.

Abbas SY, El-Sharief MA, Basyouni WM, Fakhr IM, El-Gammal EW.

Eur J Med Chem. 2013 Jun;64:111-20. doi: 10.1016/j.ejmech.2013.04.002. Epub 2013 Apr 10.

PMID:
23644194
15.

HLA-G polymorphisms and soluble HLA-G protein levels in women with recurrent pregnancy loss from Basrah province in Iraq.

Jassem RM, Shani WS, Loisel DA, Sharief M, Billstrand C, Ober C.

Hum Immunol. 2012 Aug;73(8):811-7. doi: 10.1016/j.humimm.2012.05.009. Epub 2012 May 28.

16.

Synthesis and characterization of new types of halogenated and alkylated imidazolidineiminothiones and a comparative study of their antitumor, antibacterial, and antifungal activities.

Moussa Z, El-Sharief MA, El-Sharief AM.

Eur J Med Chem. 2011 Jun;46(6):2280-9. doi: 10.1016/j.ejmech.2011.03.009. Epub 2011 Mar 10.

PMID:
21440963
17.

Polyunsaturated fatty acids in the pathogenesis and treatment of multiple sclerosis.

Harbige LS, Sharief MK.

Br J Nutr. 2007 Oct;98 Suppl 1:S46-53. Review.

PMID:
17922959
18.

Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis.

Goodin DS, Biermann LD, Bohlega S, Boiko A, Chofflon M, Gebeily S, Gouider R, Havrdova E, Jakab G, Karabudak R, Karussis D, Miller A, Pakdaman H, Selmaj K, Sharief M; International Working Group for Treatment Optimization in MS.

Curr Med Res Opin. 2007 Nov;23(11):2823-32. Review.

PMID:
17908370
19.
20.

Alternative drugs against Trichomonas vaginalis.

Mahdi NK, Gany ZH, Sharief M.

East Mediterr Health J. 2006 Sep;12(5):679-84.

21.

Infection-associated encephalopathies: their investigation, diagnosis, and treatment.

Davies NW, Sharief MK, Howard RS.

J Neurol. 2006 Jul;253(7):833-45. Epub 2006 May 24. Review.

PMID:
16715200
22.

Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis.

Frohman EM, Havrdova E, Lublin F, Barkhof F, Achiron A, Sharief MK, Stuve O, Racke MK, Steinman L, Weiner H, Olek M, Zivadinov R, Corboy J, Raine C, Cutter G, Richert J, Filippi M.

Arch Neurol. 2006 Apr;63(4):614-9. No abstract available.

PMID:
16606781
23.

Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement.

Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, Ohman S, Racke MK, Sharief M, Sindic CJ, Sellebjerg F, Tourtellotte WW.

Arch Neurol. 2005 Jun;62(6):865-70.

PMID:
15956157
24.

Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.

Schwid SR, Thorpe J, Sharief M, Sandberg-Wollheim M, Rammohan K, Wendt J, Panitch H, Goodin D, Li D, Chang P, Francis G; EVIDENCE (Evidence of Interferon Dose-Response: European North American Comparative Efficacy) Study Group; University of British Columbia MS/MRI Research Group.

Arch Neurol. 2005 May;62(5):785-92.

PMID:
15883267
25.

A double blind, randomised study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis.

Fowler CJ, Miller JR, Sharief MK, Hussain IF, Stecher VJ, Sweeney M.

J Neurol Neurosurg Psychiatry. 2005 May;76(5):700-5.

26.

Factors influencing PCR detection of viruses in cerebrospinal fluid of patients with suspected CNS infections.

Davies NW, Brown LJ, Gonde J, Irish D, Robinson RO, Swan AV, Banatvala J, Howard RS, Sharief MK, Muir P.

J Neurol Neurosurg Psychiatry. 2005 Jan;76(1):82-7.

27.

MS patient management: the Analog Model.

Sharief MK.

J Neurol. 2004 Sep;251 Suppl 5:v74-v78. Review.

PMID:
15549360
28.

Evaluation of neuromuscular symptoms in UK Gulf War veterans: a controlled study.

Rose MR, Sharief MK, Priddin J, Nikolaou V, Hull L, Unwin C, Ajmal-Ali R, Sherwood RA, Spellman A, David A, Wessely S.

Neurology. 2004 Nov 9;63(9):1681-7.

PMID:
15534255
29.

Risk factors for vaginal trichomoniasis among women in Basra, Iraq.

Mahdi NK, Gany ZH, Sharief M.

East Mediterr Health J. 2001 Nov;7(6):918-24.

30.

Garden cress lepidium sativum seeds as oral contraceptive plant in mice.

Sharief M, Gani ZH.

Saudi Med J. 2004 Jul;25(7):965-6. No abstract available.

PMID:
15235714
32.

Interferons in relapsing remitting multiple sclerosis.

Freedman M, King J, Oger J, Sharief M, Hartung HP; PRISMS study investigators.

Lancet. 2003 May 24;361(9371):1822-3; author reply 1823-4. No abstract available.

PMID:
12781558
33.

CSF hypocretin (Orexin) in neurological and psychiatric conditions.

Ebrahim IO, Semra YK, De Lacy S, Howard RS, Kopelman MD, Williams A, Sharief MK.

J Sleep Res. 2003 Mar;12(1):83-4. No abstract available.

34.

Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy.

Eikelenboom MJ, Petzold A, Lazeron RH, Silber E, Sharief M, Thompson EJ, Barkhof F, Giovannoni G, Polman CH, Uitdehaag BM.

Neurology. 2003 Jan 28;60(2):219-23.

PMID:
12552034
35.

Expression ratios of the Bcl-2 family proteins and disease activity in multiple sclerosis.

Sharief MK, Matthews H, Noori MA.

J Neuroimmunol. 2003 Jan;134(1-2):158-65.

PMID:
12507784
36.

Hypocretin (orexin) deficiency in narcolepsy and primary hypersomnia.

Ebrahim IO, Sharief MK, de Lacy S, Semra YK, Howard RS, Kopelman MD, Williams AJ.

J Neurol Neurosurg Psychiatry. 2003 Jan;74(1):127-30.

37.

Neurophysiologic analysis of neuromuscular symptoms in UK Gulf War veterans: a controlled study.

Sharief MK, Priddin J, Delamont RS, Unwin C, Rose MR, David A, Wessely S.

Neurology. 2002 Nov 26;59(10):1518-25.

PMID:
12451190
38.

Expression of CD5 on B lymphocytes correlates with disease activity in patients with multiple sclerosis.

Seidi OA, Semra YK, Sharief MK.

J Neuroimmunol. 2002 Dec;133(1-2):205-10.

PMID:
12446024
39.

Cerebral embolism complicating Libman-Sacks endocarditis--full recovery using recombinant tissue plasminogen activator.

Joven B, Mellor-Pita S, D'Cruz D, Sharief M, Khamashta M, Hughes GR.

J Rheumatol. 2002 Sep;29(9):2022-4. No abstract available.

PMID:
12233906
40.
41.

Upregulated survivin expression in activated T lymphocytes correlates with disease activity in multiple sclerosis.

Sharief MK, Noori MA, Douglas MR, Semra YK.

Eur J Neurol. 2002 Sep;9(5):503-10.

PMID:
12220382
42.

Optimizing immunomodulatory therapy for MS patients: an integrated management model.

Jeffery D, Bashir K, Buchwald L, Coyle P, Freedman M, Markowitz C, Rammohan K, Reder T, Sharief M, Wolinsky J.

J Neurol Sci. 2002 Sep 15;201(1-2):89-90. No abstract available.

PMID:
12163200
43.
44.
45.

Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit.

Silber E, Semra YK, Gregson NA, Sharief MK.

Neurology. 2002 May 14;58(9):1372-81.

PMID:
12011283
46.

The hypocretin/orexin system.

Ebrahim IO, Howard RS, Kopelman MD, Sharief MK, Williams AJ.

J R Soc Med. 2002 May;95(5):227-30. Review. No abstract available.

47.

The expression of pro- and anti-apoptosis Bcl-2 family proteins in lymphocytes from patients with multiple sclerosis.

Sharief MK, Douglas M, Noori M, Semra YK.

J Neuroimmunol. 2002 Apr;125(1-2):155-62.

PMID:
11960652
48.

A double-blind placebo-controlled clinical trial of recombinant human brain-derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy.

Wellmer A, Misra VP, Sharief MK, Kopelman PG, Anand P.

J Peripher Nerv Syst. 2001 Dec;6(4):204-10.

PMID:
11800042
49.

Small sensory fibre dysfunction in selective cholinergic dysautonomia.

Warner G, Sharief MK, Anand P.

Eur J Neurol. 2002 Jan;9(1):109. No abstract available.

PMID:
11784387
50.

Supplemental Content

Loading ...
Support Center